LiveOne Inc (LVO) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Podcast Growth ...
Audio Division Revenue (Q4 2025): $18.2 million
Adjusted EBITDA (Q4 2025): $1.1 million
Net Loss (Q4 2025): $10.9 million or $0.07 per diluted share
Full Year Consolidated Revenue (Fiscal 2025): $114.4 million
Full Year Adjusted EBITDA (Fiscal 2025): $8.4 million
Audio Division Full Year Revenue (Fiscal 2025): $108.9 million
Audio Division Adjusted EBITDA (Fiscal 2025): $18.2 million
Podcast Business Revenue (Fiscal 2025): Over $52 million, up from $38 million last year
Podcast Business Revenue (Q4 2025): $14 million
Podcast Business EBITDA (Q4 2025): Over $900,000
Guidance for Podcast Business Revenue: $55 million to $60 million
Guidance for Podcast Business EBITDA: $3.5 million to $5 million
Credit Facility: Replaced $7.5 million credit line with $27.5 million facility from JGB
Cost Reductions: Eliminated over $10 million in short-term liabilities and cut a third of staff at Slacker Radio
Subscriber and User Base: Over 1.5 million subscribers and ad-supported users
New Partnerships: $16.5 million with Amazon and $25 million with a Fortune 50 company
Stock Buyback: Over 350,000 shares of LiveOne and over a million shares of PODC
Warning! GuruFocus has detected 3 Warning Signs with LVO.
Release Date: July 03, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
LiveOne Inc (NASDAQ:LVO) reported over $112 million in revenues, surpassing previous guidance.
The podcast business achieved significant growth, with revenues increasing from $38 million to over $52 million year-over-year.
The company has successfully converted over 1.3 million Tesla users, contributing to a total of 1.5 million subscribers and ad-supported users.
LiveOne Inc (NASDAQ:LVO) has launched significant partnerships, including deals with Amazon worth $16.5 million and a Fortune 50 company worth over $25 million.
The company has made strategic financial moves, such as replacing a $7.5 million credit line with a $27.5 million facility, enhancing its cash position.
LiveOne Inc (NASDAQ:LVO) posted a consolidated net loss of $10.9 million for Q4 2025.
The company has cut a third of its staff at Slacker Radio and over 70% of its cash at CPS, indicating significant restructuring.
Despite growth, the company still faces challenges in converting ad-supported users to paid subscribers.
The company's stock has been perceived as undervalued, prompting a buyback of over 350,000 shares.
There is uncertainty regarding the financial impact of new initiatives, such as AI and Web3, as detailed guidance has not been provided.
Q: Can you clarify what a fill rate of over 50% means from a financial standpoint? A: Robert Ellin, CEO, explained that the fill rate refers to the percentage of advertising inventory being utilized, which is now over 50%. This drives revenue and sets the stage for converting free users to paid subscribers, similar to Spotify's model. The goal is to increase this fill rate to 75% quickly.
Q: Are your Web3 and crypto initiatives primarily focused on podcast content? A: Yes, Robert Ellin confirmed that the initial focus is on podcast content. LiveOne has launched a podcast network for Web3 and crypto, aiming to create and acquire content using AI. While not entering the mining business, they see opportunities in tokenization and leveraging their large audience.
Q: When will the 10-K be filed? A: Ryan Carhart, CFO, stated that the 10-K is expected to be filed early next week, pending final documentation from auditors.
Q: Can you discuss any new B2B deals or changes in deal types? A: Robert Ellin highlighted that LiveOne is experiencing significant momentum in B2B deals, similar to past successes with Tesla. They are in discussions with various industries, including carriers and streaming networks, and expect to announce a major partnership soon.
Q: Is there any update on the Tesla relationship? A: Robert Ellin expressed pride in the Tesla partnership, noting that LiveOne's branding is now prominent in Tesla cars. They have converted 1.3 million out of 2 million Tesla users, and the focus is on increasing ARPU and building a valuable subscriber database.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating
Spotify Technology S.A. (NYSE:SPOT) is among the 13 Best Global Stocks to Buy Right Now. On July 11, Keybanc lifted the stock's price target to $860 from $640, while maintaining an Overweight rating for its shares. The adjustment represents significant upside potential, given its share price of $674.46 at the close on July 23. Copyright: dennizn / 123RF Stock Photo The firm said that it expects Spotify Technology S.A. (NYSE:SPOT)'s second-quarter results and guidance for the third quarter to contain some variability related to foreign exchange, seasonal gross margin dynamics, and social charges. The analyst has advised investors to buy any near-term dips and reiterated that its core thesis remains intact. Keybanc believes that music is under-monetized in a price inflationary market with favorable competitive dynamics and several initiatives that support high-teens revenue growth. In other news, Deutsche Bank on Wednesday also raised Spotify Technology S.A. (NYSE:SPOT)'s target price to $775 from $700 and maintained a Buy rating for its shares. The Luxembourg-based company, which provides digital music-streaming services worldwide, has seen impressive returns in 2025, gaining 51% year-to-date. While we acknowledge the potential of SPOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds and 13 Best Booming Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
